Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Haemonetics Corporation for the quarter ended October 3, 1998. The company manufactures medical equipment and single-use disposables for blood processing. The fiscal year 1999 includes 53 weeks, with the additional week added to the first quarter.
Key Financial Metrics
| Metric | Three Months Ended Oct 3, 1998 | Six Months Ended Oct 3, 1998 |
|---|---|---|
| Net Revenues | $67.8 million | $139.8 million |
| Gross Profit | $31.8 million (46.9% margin) | $67.7 million (48.5% margin) |
| Operating Income | $7.9 million (11.7% margin) | $15.2 million (10.9% margin) |
| Net Income (Continuing Ops) | $5.3 million | $10.3 million |
| Net Income (Total) | $5.3 million | $10.2 million |
| Diluted EPS (Total) | $0.197 | $0.381 |
| Cash and Equivalents | $37.2 million (Balance Sheet) | $37.2 million (Balance Sheet) |
| Net Debt | $27.0 million | $27.0 million |
| Working Capital | $140.4 million | $140.4 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 6.5% for the quarter and 8.0% for the six-month period compared to the prior year. At constant currency rates, revenues were up 0.3% for the quarter but down 2.3% for the six months.
- Product Mix Shift: Equipment revenues dropped significantly (41.9% for the quarter, 58.4% for six months) due to non-recurring large shipments in 1997 (plasma equipment to China and a U.S. commercial customer). Disposable sales remained relatively stable or grew slightly at constant currency.
- Profitability: Gross profit margins improved at constant currency due to cost-saving initiatives. However, Selling, General, and Administrative (SG&A) expenses increased as a percentage of revenue for the six-month period, partly due to a $2.6 million provision for receivables related to a dispute with the American Red Cross.
- Discontinued Operations: The company is divesting its Blood Bank Management Services (BBMS) business. Operating losses for BBMS were charged to a reserve established in the prior fiscal year, resulting in minimal impact on current net income.
- Liquidity: Net debt decreased by $21.8 million to $27.0 million as the company used strong operating cash flow ($25.2 million for continuing operations) to pay down debt.
Guidance, Outlook, and Risks
- Year 2000 Compliance: Management estimates total compliance costs between $3 million and $4 million. Approximately 90% of system-related exposures have been inventoried. The company anticipates completing remediation of critical systems by June 30, 1999. Risks include potential failures in untested microchips and vendor non-compliance.
- Outlook: The company expects an annualized tax rate of approximately 35% for fiscal 1999. No share repurchases are expected during the current fiscal year.
- Contingencies: A formal contingency plan for Year 2000 issues is expected by March 31, 1999. The company notes that failure of key vendors to be compliant could materially affect business operations.
Investor Verification Checklist
- Verify the status of the dispute with the American Red Cross and the adequacy of the $2.6 million receivable provision.
- Monitor the progress of the Year 2000 remediation plan, specifically regarding critical vendors and untested production equipment microchips.
- Assess the sustainability of equipment revenue growth given the absence of the large 1997 non-recurring shipments.
- Review the timeline for the sale of remaining Blood Bank Management Services (BBMS) operations to ensure full exit from the discontinued segment.
- Confirm the impact of foreign currency fluctuations on future margins, as international sales represent approximately 68% of revenue.